ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6195
0.07%
Brent Oil
83.76
0.00%
Bitcoin
66,123.28
-1.22%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Supernus Pharmaceuticals Inc (SUPN)

  7. Supernus Pharmaceuticals Inc (SUPN) Noticias

SUPN

Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SUPN
FechaHoraFuenteTítuloSímboloCompañía
09/05/202415:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
09/05/202415:05GlobeNewswire Inc.Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant SeizuresNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202415:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202415:05GlobeNewswire Inc.Supernus Announces First Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
07/05/202409:00PR Newswire (US)M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin AmericaNASDAQ:SUPNSupernus Pharmaceuticals Inc
01/05/202407:00GlobeNewswire Inc.Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree StoryNASDAQ:SUPNSupernus Pharmaceuticals Inc
24/04/202415:05GlobeNewswire Inc.Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024NASDAQ:SUPNSupernus Pharmaceuticals Inc
08/04/202407:00GlobeNewswire Inc.Supernus Provides Regulatory Update for SPN-830NASDAQ:SUPNSupernus Pharmaceuticals Inc
06/03/202415:30GlobeNewswire Inc.Supernus to Participate in Two Upcoming Investor ConferencesNASDAQ:SUPNSupernus Pharmaceuticals Inc
29/02/202416:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
28/02/202415:30GlobeNewswire Inc.Supernus to Participate in the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202415:14Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202415:05GlobeNewswire Inc.Supernus Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/02/202415:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
14/02/202413:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SUPNSupernus Pharmaceuticals Inc
14/02/202406:06Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SUPNSupernus Pharmaceuticals Inc
13/02/202415:05GlobeNewswire Inc.Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024NASDAQ:SUPNSupernus Pharmaceuticals Inc
05/02/202407:30GlobeNewswire Inc.Supernus Wins Infringement and Validity Case on Trokendi XR® against TorrentNASDAQ:SUPNSupernus Pharmaceuticals Inc
19/12/202306:30GlobeNewswire Inc.Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in CanadaNASDAQ:SUPNSupernus Pharmaceuticals Inc
12/12/202304:50IH Market NewsHasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and MoreNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/11/202315:05GlobeNewswire Inc.Supernus Announces Third Quarter 2023 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
07/11/202315:30GlobeNewswire Inc.Supernus to Participate in the Jefferies London Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
02/11/202306:00GlobeNewswire Inc.Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDANASDAQ:SUPNSupernus Pharmaceuticals Inc
25/10/202315:15GlobeNewswire Inc.Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023NASDAQ:SUPNSupernus Pharmaceuticals Inc
16/10/202316:34GlobeNewswire Inc.Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® JourneyNASDAQ:SUPNSupernus Pharmaceuticals Inc
09/10/202316:45Dow Jones NewsSupernus Resubmits NDA to FDA for Apomorphine Infusion Device to Treat Parkinson'sNASDAQ:SUPNSupernus Pharmaceuticals Inc
09/10/202315:45GlobeNewswire Inc.Supernus Resubmits NDA for SPN-830 Apomorphine Infusion DeviceNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/09/202315:15GlobeNewswire Inc.Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York CityNASDAQ:SUPNSupernus Pharmaceuticals Inc
09/09/202319:00GlobeNewswire Inc.Supernus Announces New Qelbree® Data Showing Improvement in ADHD SymptomsNASDAQ:SUPNSupernus Pharmaceuticals Inc
31/08/202316:30GlobeNewswire Inc.Supernus to Participate in the Wells Fargo Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SUPN

Su Consulta Reciente

USOTC
GRCMF
Green Shift Commodities (QB)
EU
E808T
E808T
LSE
48UZ
Sigma Fin. 16
EU
MLPVG
Groupe Plus Values
TG
10AM
Amundi Index Global Agg ...
LSE
67AR
Sigma Fin.nt08
NASDAQ
FXXEIX
Leisure & Entertainment ...
LSE
35GM
Sinfonia Nts 41
EU
VIEAR
Veolia Environnement SA ...
TG
OYC
Delta Air Lines
TSXV
CYP
Cypress Development
LSE
RC27
Diageo Bv 29
BIT
F14200
Vontobel Financial Produ...
LSE
CJ47
Orbta 22-1.29 C
LSE
SE01
Sg Issuer 30
LSE
92TK
Sg Issuer 29
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados